Advertisement
News
Advertisement

Quantum Materials Corp and Nanoaxis Announce Technology Alliance

Tue, 09/20/2011 - 8:34am
Bio-Medicine.Org

TEMPE, Ariz., Sept. 20, 2011 /PRNewswire/ -- Quantum Materials Corporation (www.qdotss.com ) (Pink Sheets: QTMM) Quantum Materials Corp. and Nanoaxis, LLC announce the formation of a technology alliance combining Quantum Materials tetrapod quantum dot mass production technology with Nanoaxis advanced research expertise and intellectual property in gene therapy biomedical nanotechnology.  The aim of the alliance is to develop Tetrapod Quantum Dot based Cancer diagnostic kits and theranostic applications including Alzheimer's, Type 1 and Type 2 Diabetes, Breast Cancer and Major Depression.

Quantum Materials Corporation will develop specialized quantum dots for Nanoaxis to functionalize with their proprietary biomedical nanomaterials for a multiplexing drug delivery platform for drug/gene therapy and diagnostic medical devices technologies. The technology alliance allows these technologies to be developed rapidly due to Quantum Materials' ability to create the highest quality quantum dots in quantities necessary to support multiple projects with timely deliveries.

The immediate goal is to develop a QD microarray device for detection, diagnosis and quantification of early cancers. The QD-MI device will be designed for rapid detection and grading of various multiple cancers using blood assays, with higher accuracy and at less cost than current single ELISA assays. All diagnostic and pharmaceutical products will include QMC quantum dots functionalized by Nanoaxis biomedical IP nanotechnology.

According to a recent report published by BCC Research the total market for nanobiotechnology products is $19.3 billion in 2010 and is growing at a compound annual growth rate (CAGR) of 9% to reach a forecast market size of $29.7 billion by 2015.

Stephen Squires, CEO and President of

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading